» Articles » PMID: 28106842

Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins As Anti-Cancer Agents

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2017 Jan 21
PMID 28106842
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is a devastating disease that affects millions of patients every year, and causes an enormous economic burden on the health care system and emotional burden on affected families. The first line of defense against solid tumors is usually extraction of the tumor, when possible, by surgical methods. In cases where solid tumors can not be safely removed, chemotherapy is often the first line of treatment. As metastatic cancers often become vigorously resistant to treatments, the development of novel, more potent and selective anti-cancer strategies is of great importance. Adenovirus (Ad) is the most commonly used virus in cancer clinical trials, however, regardless of the nature of the Ad-based therapeutic, complete responses to treatment remain rare. A number of pre-clinical studies have shown that, for all vector systems, viral spread throughout the tumor mass can be a major limiting factor for complete tumor elimination. By expressing exogenous cell-fusion proteins, many groups have shown improved spread of Ad-based vectors. This review summarizes the research done to examine the potency of Ad vectors expressing fusogenic proteins as anti-cancer therapeutics.

Citing Articles

Development and Characterization of an Oncolytic Human Adenovirus-Based Vector Co-Expressing the Adenovirus Death Protein and p14 Fusion-Associated Small Transmembrane Fusogenic Protein.

Poulin K, Clarkin R, Del Papa J, Parks R Int J Mol Sci. 2024; 25(22).

PMID: 39596515 PMC: 11594305. DOI: 10.3390/ijms252212451.


Gold Nanoparticle-Assisted Virus Formation by Means of the Delivery of an Oncolytic Adenovirus Genome.

Sendra L, Miguel A, Navarro-Plaza M, Herrero M, de la Higuera J, Chafer-Pericas C Nanomaterials (Basel). 2020; 10(6).

PMID: 32560474 PMC: 7353451. DOI: 10.3390/nano10061183.


An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate .

Del Papa J, Petryk J, Bell J, Parks R Mol Ther Oncolytics. 2019; 14:107-120.

PMID: 31193718 PMC: 6539411. DOI: 10.1016/j.omto.2019.05.001.


Myoblast fusion confusion: the resolution begins.

Sampath S, Sampath S, Millay D Skelet Muscle. 2018; 8(1):3.

PMID: 29386054 PMC: 5793351. DOI: 10.1186/s13395-017-0149-3.

References
1.
DeWeese T, Van der Poel H, Li S, Mikhak B, Drew R, Goemann M . A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001; 61(20):7464-72. View

2.
Heise C, Williams A, Olesch J, Kirn D . Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 1999; 6(6):499-504. DOI: 10.1038/sj.cgt.7700071. View

3.
OMalley R, Mariano T, Siekierka J, Mathews M . A mechanism for the control of protein synthesis by adenovirus VA RNAI. Cell. 1986; 44(3):391-400. DOI: 10.1016/0092-8674(86)90460-5. View

4.
Asghar U, Witkiewicz A, Turner N, Knudsen E . The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015; 14(2):130-46. PMC: 4480421. DOI: 10.1038/nrd4504. View

5.
Smith E, Breznik J, Lichty B . Strategies to enhance viral penetration of solid tumors. Hum Gene Ther. 2011; 22(9):1053-60. DOI: 10.1089/hum.2010.227. View